HCV Protease Inhibitor Sovaprevir Placed on Hold Due to Interaction with HIV Drug

In early July the U.S. Food and Drug Administration put a clinical hold on Achillion's investigational hepatitis C virus protease inhibitor sovaprevir due to unexpected liver enzyme elevations observed in healthy volunteers taking sovaprevir with the HIV protease inhibitor atazanavir in an early drug-drug interaction study.

http://www.hivandhepatitis.com/hcv-treatment/experimental-hcv-drugs/4216-hcv-protease-inhibitor-sovaprevir-placed-on-hold-due-to-interaction-with-hiv-drug